12.47
0.14 (1.14%)
| Previous Close | 12.33 |
| Open | 12.36 |
| Volume | 92,284 |
| Avg. Volume (3M) | 314,978 |
| Market Cap | 416,802,272 |
| Price / Book | 2.07 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 23.31 |
| Operating Cash Flow (TTM) | -66.65 M |
| Levered Free Cash Flow (TTM) | -42.10 M |
| Return on Assets (TTM) | -31.68% |
| Return on Equity (TTM) | -48.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | MBX Biosciences, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.12% |
| % Held by Institutions | 106.60% |
| 52 Weeks Range | ||
| Median | 38.00 (204.73%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 16 Jul 2025 | 38.00 (204.73%) | Buy | 12.43 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development |
| 16 Jun 2025 | Announcement | MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity |
| 10 Jun 2025 | Announcement | MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions |
| 20 May 2025 | Announcement | MBX Biosciences to Participate in June Investor Conferences |
| 12 May 2025 | Announcement | MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |